Sep 14, 2023 4:05pm EDT Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Jun 27, 2023 4:05pm EDT Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
May 11, 2023 4:05pm EDT Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
Mar 23, 2023 4:50pm EDT Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
Mar 08, 2023 7:00am EST Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Feb 10, 2023 4:05pm EST Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Dec 15, 2022 7:00am EST Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
Nov 09, 2022 4:05pm EST Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
